Malaria Vaccine Advisory Committee (MALVAC) meeting on Preferred Product Characteristics for malaria vaccines

Malaria Vaccine Advisory Committee (MALVAC) meeting on Preferred Product Characteristics for malaria vaccines: report of a meeting, 27–28 October 2020

On 27–28 October 2020, the WHO Initiative for Vaccine Research and Global Malaria Programme convened a meeting of the Malaria Vaccine Advisory Committee (MALVAC) to review priority issues in product development in malaria vaccine research and development (R&D). Experts reviewed major use case scenarios for malaria vaccines, including the reduction of morbidity and mortality, and the reduction of malaria transmission. Other potential use case scenarios were also discussed, including seasonal vaccination, vaccination to prevent malaria in pregnancy, and vaccines targeting non-Plasmodium falciparum species such as P. vivax. MALVAC members discussed how best to update and build on the previously developed malaria vaccine Preferred Product Characteristics, bearing in mind advances in the field and lessons learned from the development and evaluation of the RTS,S/AS01E vaccine.